Extended treatment response to imatinib in Rosai-Dorfman disease

Eur J Haematol. 2021 Jun;106(6):868-870. doi: 10.1111/ejh.13605. Epub 2021 Mar 4.

Authors

Avani Singh¹, Yael Simons², John Biren-Fetz³, Gayatry Mohapatra⁴, Hongyu Ni⁴, Sujata Gaitonde⁴, Irum Khan²

Affiliations

¹ Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
² Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
³ Department of Radiology, University of Illinois at Chicago, Chicago, IL, USA.
⁴ Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.

PMID: 33619765
DOI: 10.1111/ejh.13605

No abstract available

Keywords: Rosai-Dorfman disease; histiocytosis; imatinib.

Publication types

Case Reports

MeSH terms

Adult
Diagnosis, Differential
Female
Histiocytosis, Sinus / diagnosis
Histiocytosis, Sinus / drug therapy*
Histiocytosis, Sinus / metabolism
Histiocytosis, Sinus / pathology
Humans
Imatinib Mesylate / administration & dosage*

Substances

Imatinib Mesylate